New therapeutic perspectives in HBV: When to stop NAs

Liver International

Volumn 34, Issue SUPPL1, 2014, Pages 146-153

  Pérez Cameo, Cristina ^a   Pons, Mònica ^a   Esteban, Rafael ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Chronic hepatitis B; Nucleos(t)ide analogues; Treatment

Indexed keywords

ADEFOVIR; ENTECAVIR; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; NUCLEOSIDE ANALOG; TELBIVUDINE; TENOFOVIR;

ANTIBODY TITER; ANTIVIRAL THERAPY; DRUG TOLERABILITY; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LONG TERM CARE; PRACTICE GUIDELINE; PROTEIN BLOOD LEVEL; RELAPSE; REVIEW; SEROCONVERSION; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS REPLICATION;

CHRONIC HEPATITIS B; NUCLEOS(T)IDE ANALOGUES; TREATMENT;

ADENINE; ALGORITHMS; ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; DNA, VIRAL; DRUG THERAPY, COMBINATION; GUANINE; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; INTERFERON-ALPHA; LAMIVUDINE; NUCLEOSIDES; ORGANOPHOSPHONATES; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; THYMIDINE;

EID: 84890877852     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12398     Document Type: Review

References (41)

1. European Association For The Study Of The Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol 2012; 57: 167-85.
2. Lok ASF, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50: 661-2.
3. Liaw Y-F, Leung N, Kao J-H, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int 2008; 2: 263-83.
4. Liaw Y-F, Kao J-H, Piratvisuth T, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int 2012; 6: 531-61.
5. Pan X, Zhang K, Yang X, et al. Relapse rate and associated-factor of recurrence after stopping NUCs therapy with different prolonged consolidation therapy in HBeAg positive CHB patients. PLoS One 2013; 8: e68568.
6. Ruan P, Xu S-Y, Zhou B-P, Huang J, Gong Z-J. Hepatitis B surface antigen seroclearance in patients with chronic hepatitis B infection: a clinical study. J Int Med Res 2013; 41: 1732-9.
7. Chu C-M, Liaw Y-F. Hepatitis B surface antigen seroclearance during chronic HBV infection. Antivir Ther 2010; 15: 133-43.
8. Liang Y, Jiang J, Su M, et al. Predictors of relapse in chronic hepatitis B after discontinuation of anti-viral therapy: stopping anti-viral therapy in hepatitis B. Aliment Pharmacol Ther 2011; 34: 344-52.
9. Ahn SH, Chan HLY, Chen P-J, et al. APPROACH Working Group. Chronic hepatitis B: whom to treat and for how long? Propositions, challenges, and future directions. Hepatol Int 2010; 4: 386-95.
10. Moucari R, Marcellin P. HBsAg seroclearance: prognostic value for the response to treatment and the long-term outcome. Gastroentérologie Clin Biol 2010; 34(Suppl. 2): S119-25.
11. Chan HL-Y, Thompson A, Martinot-Peignoux M, et al. Hepatitis B surface antigen quantification: why and how to use it in 2011 - a core group report. J Hepatol 2011; 55: 1121-31.
12. Brunetto MR, Moriconi F, Bonino F, et al. Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Hepatology 2009; 49: 1141-50.
13. Su T-H, Liu C-J, Yang H-C, et al. Clinical significance and evolution of hepatic HBsAg expression in HBeAg-positive patients receiving interferon therapy. J Gastroenterol 2013. DOI:10.1007/s00535-013-0840-z.
14. Van Zonneveld M, Honkoop P, Hansen BE, et al. Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B. Hepatology 2004; 39: 804-10.
15. Sonneveld MJ, Rijckborst V, Cakaloglu Y, et al. Durable hepatitis B surface antigen decline in hepatitis B e antigen-positive chronic hepatitis B patients treated with pegylated interferon-α2b: relation to response and HBV genotype. Antivir Ther 2012; 17: 9-17.
16. Chan HL-Y, Wong VW-S, Chim AM-L, et al. Serum HBsAg quantification to predict response to peginterferon therapy of e antigen positive chronic hepatitis B. Aliment Pharmacol Ther 2010; 32: 1323-31.
17. Gane E, Jia J, Han K, et al. 69 NEPTUNE study: on-treatment HBsAg level analysis confirms prediction of response observed in phase-3 study of peginterferon alfa-2A in HBeAg-positive patients. J Hepatol 2011; 54: S31.
18. Sonneveld MJ, Rijckborst V, Boucher CAB, Hansen BE, Janssen HLA. Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline. Hepatology 2010; 52: 1251-7.
19. Buster EHCJ, Hansen BE, Lau GKK, et al. Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa. Gastroenterology 2009; 137: 2002-9.
20. Moucari R, Mackiewicz V, Lada O, et al. Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. Hepatology 2009; 49: 1151-7.
21. Marcellin P, Bonino F, Lau GKK, et al. Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alfa-2a. Gastroenterology 2009; 136: 2169-79. e4.
22. Rijckborst V, Hansen BE, Ferenci P, et al. Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a. J Hepatol 2012; 56: 1006-11.
23. Bonino F, Marcellin P, Lau GKK, et al. Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B. Gut 2007; 56: 699-705.
24. Marcellin P, Gane E, Buti M, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet 2013; 381: 468-75.
25. Tanaka E, Matsumoto A. Guidelines for avoiding risks resulting from discontinuation of nucleoside/nucleotide analogs in patients with chronic hepatitis B: guidelines to discontinue NUC. Hepatol Res 2013. doi:10.1111/hepr.12108.
26. Song MJ. Durability of viral response after off-treatment in HBeAg positive chronic hepatitis B. World J Gastroenterol 2012; 18: 6277.
27. Kwon JH, Jang JW, Choi JY, et al. Should lamivudine monotherapy be stopped or continued in patients infected with hepatitis B with favorable responses after more than 5 years of treatment? J Med Virol 2013; 85: 34-42.
28. Jin Y-J, Kim KM, Yoo D, et al. Clinical course of chronic hepatitis B patients who were off-treated after lamivudine treatment: analysis of 138 consecutive patients. Virol J 2012; 9: 239.
29. Marcellin P, Chang T-T, Lim SGL, et al. Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2008; 48: 750-8.
30. Hadziyannis SJ, Sevastianos V, Rapti I, Vassilopoulos D, Hadziyannis E. Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovir. Gastroenterology 2012; 143: 629-36. e1.
31. Tsai M-C, Chen C-H, Hung C-H, et al. A comparison of efficacy and safety of 2-year telbivudine and entecavir treatment in patients with chronic hepatitis B: a match-control study. Clin Microbiol Infect 2013. DOI:10.1111/1469-0691.12220.
32. Li X, Wang Y, Han D, et al. Correlation of hepatitis B surface antigen level with response to telbivudine in naive patients with chronic hepatitis B: HBsAg level and telbivudine treatment efficacy. Hepatol Res 2013. DOI:10.1111/hepr.12105.
33. Marcellin P, Heathcote EJ, Buti M, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008; 359: 2442-55.
34. Heathcote EJ, Marcellin P, Buti M, et al. Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology 2011; 140: 132-43.
35. Shouval D, Lai C-L, Chang T-T, et al. Relapse of hepatitis B in HBeAg-negative chronic hepatitis B patients who discontinued successful entecavir treatment: the case for continuous antiviral therapy. J Hepatol 2009; 50: 289-95.
36. Gish RG, Lok AS, Chang T-T, et al. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology 2007; 133: 1437-44.
37. Jeng W-J, Sheen I-S, Chen Y-C, et al. Off therapy durability of response to entecavir therapy in hepatitis B e antigen negative chronic hepatitis B patients. Hepatology 2013; 58: 1888-96.
38. Tseng T-C, Kao J-H. Clinical utility of quantitative HBsAg in natural history and nucleos(t)ide analogue treatment of chronic hepatitis B: new trick of old dog. J Gastroenterol 2013; 48: 13-21.
39. Seto W-K, Wong DK-H, Fung J, et al. Reduction of hepatitis B surface antigen levels and hepatitis B surface antigen seroclearance in chronic hepatitis B patients receiving 10 years of nucleoside analogue therapy. Hepatology 2013; 58: 923-31.
40. Martinot-Peignoux M, Lapalus M, Laouénan C, et al. Prediction of disease reactivation in asymptomatic hepatitis B e antigen-negative chronic hepatitis B patients using baseline serum measurements of HBsAg and HBV-DNA. J Clin Virol 2013; 58: 401-7.
41. Petersen J, Buggisch P, Hinrichsen H, et al. Stopping long-term nucleos(t)ide analogue therapy before HBsAg loss in HbeAg negative CHB patients: follow-up of long term responders. J Hepatol 2013; 58: S313.